We thank Gionata Fiorino and colleagues and Jonathan Segal and colleagues for their comments on our Correspondence.[@bib1] Here we seek to clarify some details. The early transmission kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were described[@bib2] as a basic reproductive number estimated at 2·2 (95% CI 1·4--3·9) and a doubling of cases every 7·4 days, together with a case-fatality rate of 3·67% in Wuhan, China. Lack of knowledge and community awareness of coronavirus disease 2019 (COVID-19) along with the severity of suspected cases, possible high transmission, and the peak of the Spring Festival in China during the early stages of the outbreak, made the task of minimising the risk of transmission to our patients with inflammatory bowel disease (IBD) urgent and all the more difficult. Because immunosuppressive drugs have previously been shown to increase the risk of opportunistic infections, use of such drugs was put on hold. This approach was subsequently adopted in guidance from the Chinese Gastroenterology Society, which recommended halting biologics in high-risk areas.[@bib3]

We acknowledge that most published guidelines have advocated for the continuation of biological therapy and we understand the Fiorino and colleagues\' concerns about an increased risk of disease recurrence and negative outcomes after stopping immunosuppressive therapy. However, in our study effective communication with our patients allowed us to rapidly give attention to patients with disease flares, such that only 12 (3·8%) of 318 patients were admitted to hospital, with only one requiring emergent surgery (intestinal perforation), during the entire 3-month lockdown period. Our short-term medical transitions did not result in increased recurrence compared with before the outbreak (data not shown). Because the COVID-19 outbreak has come under control in Wuhan, China, and given the emergence of literature regarding COVID-19, we restarted the use of immunosuppressive medications and biological therapy in our patients from April 1, 2020. Prevention of infection when encountering a new, deadly, and highly transmissible infectious organism requires caution and respect for the entity.

Low doses of the steroid prednisolone (20 mg) have been suggested as a treatment for patients with IBD and COVID-19.[@bib4] Although we agree with Fiorino and colleagues that the risk of disease recurrence and negative outcomes might be increased due to stopping immunosuppressive therapy, many of these medications have a long wash-out period[@bib5] and disease recurrence was not substantially increased in our cohort in the short term.

We agree with Segal and colleagues that inherent differences exist between western populations and eastern populations, including in the prevalence of IBD. The social media platform WeChat is near ubiquitous in China; the multiple platforms in use elsewhere might help in managing patient communications.

Local guidelines and isolation measures should be dictated by the background incidence of COVID-19 in the community. A great many unknowns remain and the situation is still dynamic. We will continue to monitor our patients closely during the follow-up period for flares of disease activity and complications of switching medications, including restarting patients on their original biological therapy.
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